World news story

UK and India regulators agree deal for closer collaboration to improve public safety

This is the first MOU agreed with the Central Drugs Standard Control Organisation (CDSCO), part of the Ministry of Health and Family Welfare of India.

MHRA MoU signing

The Medicines and Healthcare products Regulatory Agency (MHRA) UK has today signed a Memorandum of Understanding (MOU) with its counterpart body in India. This agreement will increase collaboration between the two countries in the area of medicines and medical devices with the aim of further improving public safety in the two countries.

This is the first MOU agreed with the Central Drugs Standard Control Organisation (CDSCO), part of the Ministry of Health and Family Welfare of India. It was signed by Dr Gyanendra Nath Singh, India’s Drugs Controller General, and MHRA Chairman, Professor Sir Michael Rawlins. It provides a formal agreement between the two organisations, and strengthens relations between the UK and Indian governments.

The central understandings of the agreement include promotion of each other’s regulatory frameworks, requirements and processes. Significant outcomes will include the facilitation and exchange of information and opportunities for technical cooperation of mutual benefit, helping to ensure the regulators are better equipped to protect the health of their respective publics.

MHRA Chairman, Professor Sir Michael Rawlins said:

We are committed to protecting the health of UK citizens and that’s why we are continuing to formalise our collaborative efforts with key partners like India.

We operate in a global environment and agreements such as these serve to further strengthen our ability to promote good practices and we look forward to working even closer with our Indian counterparts.

Drugs Controller General India, Dr Gyanendra Nath Singh commented:

The MoU signed between MHRA and CDSCO is going to create a new platform where patients will be given utmost importance. Quality medicine, affordability and transparency will be the tools for making medicines available to the people of the two nations.

In 2014, MHRA carried out more 550 inspections in the UK and 125 in non-EU countries, 49 of which were in India. The India Brand Equity Foundation states that the Indian pharma sector accounts for about 2.4% of the global pharma industry and is the 3rd largest in terms of volume.

Each batch of medicine imported into the UK from India is tested on importation to ensure it is safe, of good quality and effective and it is important that MHRA assessors continue to inspect Indian sites to ensure Good Manufacturing Practice – a globally recognised regulatory framework.

Sir Michael Rawlins added:

It’s essential that the commitment to good quality manufacturing comes right down from the top levels of management to those on the factory floor, and throughout the entire industry.

Indian firms already accept and understand this, and the MOU is part of a concerted effort to ensure the UK and wider global public continue to have access to quality and safe medicines.

The signing of the MOU took place at CDSCO’s headquarters in New Delhi and was followed by a series of meetings to discuss next steps.

The agreement is similar to those already in place between MHRA and other counterpart bodies in China and the USA, although it is a standalone bilateral document in its own right.

Further information:

  1. The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating all medicines and medical devices in the UK by ensuring they work and are acceptably safe. All our work is underpinned by robust and fact-based judgements to ensure that the benefits justify any risks. MHRA is a centre of the Medicines and Healthcare products Regulatory Agency which also includes NIBSC and CPRD. The Medicines and Healthcare products Regulatory Agency is an executive agency of the Department of Health.

  2. The Central Drugs Standard Control Organization is the lead authority for discharging functions assigned by the Government of India under the Drugs and Cosmetics Act. It has six zonal offices, four sub-zonal offices, 13 port offices and seven laboratories under its control.

  3. Photos of MoU signing:

For further information email or contact MHRA at:

MHRA, Press Office
020 3080 7651
Out of hours 07770 446 189

Follow us on Twitter, Facebook, Flickr, Storify, Eventbrite, Blogs, Foursquare, Youtube, Instagram, Vine, Snapchat @UKinIndia, Periscope @UKinIndia

Published 5 October 2015